The use of long-acting injectables in early-phase schizophrenia 

被引：0
|
作者：
Tiihonen, Jari [1 ,2 ,3 ]
机构：
[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[2] Stockholm Hlth Care Serv, Ctr Psychiat Res, Stockholm, Region Stockhol, Sweden
[3] Univ Eastern Finland, Niuvanniemi Hosp, Dept Forens Psychiat, Kuopio, Finland
来源：
LANCET PSYCHIATRY | 2023年 / 10卷 / 07期
关键词：
D O I：
10.1016/S2215-0366(23)00141-4
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：481 / 482
页数：2
相关论文
共 50 条
  • [31] Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial
    Kane, John M.
    Schooler, Nina R.
    Marcy, Patricia
    Correll, Christoph U.
    Achtyes, Eric D.
    Gibbons, Robert D.
    Robinson, Delbert G.
    JAMA PSYCHIATRY, 2020, 77 (12) : 1217 - 1224
  • [32] Long-Acting Injectables: Current Perspectives and Future Promise
    Chaudhary, Komal
    Patel, Mayur M.
    Mehta, Priti J.
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2019, 36 (02): : 137 - 181
  • [33] Leveraging Model Master Files for Long-Acting Injectables
    Gong, Yuqing
    Hopefl, Robert
    Li, Tonglei
    Hooker, Andrew C.
    Silva, Daniela Amaral
    Alam, Khondoker
    Ducharme, Murray
    Moody, Rebecca
    Saha, Pratik
    Babiskin, Andrew
    PHARMACEUTICAL RESEARCH, 2025,
  • [34] Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia
    Song, Xue
    El Khoury, Antoine C.
    Brouillette, Matthew
    Smith, David
    Joshi, Kruti
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) : 1105 - 1112
  • [35] Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
    Mahlich, Joerg
    Olbrich, Kerstin
    Wilk, Adrian
    Wimmer, Antonie
    Wolff-Menzler, Claus
    CLINICAL DRUG INVESTIGATION, 2021, 41 (01) : 99 - 113
  • [36] Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
    Jörg Mahlich
    Kerstin Olbrich
    Adrian Wilk
    Antonie Wimmer
    Claus Wolff-Menzler
    Clinical Drug Investigation, 2021, 41 : 99 - 113
  • [37] Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics
    MacEwan, Joanna P.
    Kamat, Siddhesh A.
    Duffy, Ruth A.
    Seabury, Seth
    Chou, Jacquelyn W.
    Legacy, Susan N.
    Hartry, Ann
    Eramo, Anna
    Karson, Craig
    PSYCHIATRIC SERVICES, 2016, 67 (11) : 1183 - 1188
  • [38] Long-Acting Injectables and Risk for Rehospitalization Among Patients With Schizophrenia in the Home Care Program in Taiwan
    Ju, Po-Chung
    Chou, Frank Huang-Chih
    Lai, Te-Jen
    Chuang, Po-Ya
    Lin, Yung-Jung
    Yang, Ching-Wen Wendy
    Tang, Chao-Hsiun
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (01) : 23 - 29
  • [39] Long-acting risperidone - A review of its use in schizophrenia
    Harrison, TS
    Goa, KL
    CNS DRUGS, 2004, 18 (02) : 113 - 132
  • [40] Long-Acting Risperidone: A Review of Its Use in Schizophrenia
    Harrison T.S.
    Goa K.L.
    CNS Drugs, 2004, 18 (2) : 113 - 132
12345